Pathogenesis of non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 29, Issue 14, 2011, Pages 1803-1811

  Nogai, Hendrik ^a   Dörken, Bernd ^a   Lenz, Georg ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE; BURKITT LYMPHOMA; CARCINOGENESIS; CELL MATURATION; FOLLICULAR LYMPHOMA; GENETIC ASSOCIATION; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

B-LYMPHOCYTES; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 79955835059     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.3252     Document Type: Review

References (77)

1. Fugmann SD, Lee AI, Shockett PE, et al: The RAG proteins and V(D)J recombination: Complexes, ends, and transposition. Annu Rev Immunol 18:495-527, 2000
2. Rajewsky K: Clonal selection and learning in the antibody system. Nature 381:751-758, 1996
3. Muramatsu M, Kinoshita K, Fagarasan S, et al: Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102:553-563, 2000
4. Goossens T, Klein U, Kuppers R: Frequent occurrence of deletions and duplications during somatic hypermutation: Implications for oncogene translocations and heavy chain disease. Proc Natl Acad Sci U S A 95:2463-2468, 1998 (Pubitemid 28145964)
5. Manis JP, Tian M, Alt FW: Mechanism and control of class-switch recombination. Trends Immunol 23:31-39, 2002 (Pubitemid 34098959)
6. Bakhshi A, Jensen JP, Goldman P, et al: Cloning the chromosomal breakpoint of t(14;18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41:899-906, 1985 (Pubitemid 15243395)
7. Raghavan SC, Swanson PC, Wu X, et al: A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex. Nature 428:88-93, 2004 (Pubitemid 38332363)
8. Migliazza A, Martinotti S, Chen W, et al: Frequent somatic hypermutation of the 5′ noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci U S A 92:12520-12524, 1995
9. Wang X, Li Z, Naganuma A, et al: Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. Proc Natl Acad Sci U S A 99:15018-15023, 2002 (Pubitemid 35334602)
10. Pasqualucci L, Neumeister P, Goossens T, et al: Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412:341-346, 2001 (Pubitemid 32691848)
11. Liu M, Duke JL, Richter DJ, et al: Two levels of protection for the B cell genome during somatic hypermutation. Nature 451:841-845, 2008 (Pubitemid 351253166)
12. Bergsagel PL, Chesi M, Nardini E, et al: Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A 93:13931-13936, 1996 (Pubitemid 26424223)
13. Nardini E, Aiello A, Giardini R, et al: Detection of aberrant isotype switch recombination in low-grade and high-grade gastric MALT lymphomas. Blood 95:1032-1038, 2000 (Pubitemid 30062728)
14. Ramiro AR, Jankovic M, Eisenreich T, et al: AID is required for c-myc/IgH chromosome translocations in vivo. Cell 118:431-438, 2004 (Pubitemid 39485663)
15. Lenz G, Nagel I, Siebert R, et al: Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 204:633-643, 2007 (Pubitemid 46457085)
16. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: The Non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-3918, 1997
17. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000 (Pubitemid 30082188)
18. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
19. Rosenwald A, Wright G, Leroy K, et al: Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:851-862, 2003 (Pubitemid 37152922)
20. Savage KJ, Monti S, Kutok JL, et al: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871-3879, 2003 (Pubitemid 37486965)
21. Turner CA Jr, Mack DH, Davis MM: Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin- secreting cells. Cell 77:297-306, 1994 (Pubitemid 24138626)
22. Tam W, Gomez M, Chadburn A, et al: Mutational analysis of PRDM1 indicates a tumor suppressor role in diffuse large B-cell lymphomas. Blood 107:4090-4100, 2006 (Pubitemid 43726818)
23. Pasqualucci L, Compagno M, Houldsworth J, et al: Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 203:311-317, 2006 (Pubitemid 43290840)
24. Iqbal J, Greiner TC, Patel K, et al: Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 21:2332-2343, 2007 (Pubitemid 350011706)
25. Lenz G, Wright GW, Emre NC, et al: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105:13520-13525, 2008
26. Bea S, Zettl A, Wright G, et al: Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 106:3183-3190, 2005 (Pubitemid 41565917)
27. Schmidlin H, Diehl SA, Nagasawa M, et al: Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression. Blood 112:1804-1812, 2008
28. Joos S, Otano-Joos MI, Ziegler S, et al: Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87:1571-1578, 1996 (Pubitemid 26056923)
29. Joos S, Kupper M, Ohl S, et al: Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60:549-552, 2000 (Pubitemid 30094549)
30. Xiao C, Srinivasan L, Calado DP, et al: Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9:405-414, 2008 (Pubitemid 351405110)
31. Morin RD, Johnson NA, Severson TM, et al: Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42:181-185, 2010
32. Su GH, Chen HM, Muthusamy N, et al: Defective B cell receptor-mediated responses in mice lacking the Ets protein, Spi-B. EMBO J 16:7118-7129, 1997 (Pubitemid 27520810)
33. Davis RE, Brown KD, Siebenlist U, et al: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194:1861-1874, 2001
34. Lam LT, Wright G, Davis RE, et al: Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- {kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 111:3701-3713, 2008
35. Lam LT, Davis RE, Wright G, et al: Small molecule inhibitors of IkB-kinase are selectively toxic for subgroups of diffuse large B cell lymphoma defined by gene expression profiling. Clin Cancer Res 11:28-40, 2005 (Pubitemid 40075775)
36. Ngo VN, Davis RE, Lamy L, et al: A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441:106-110, 2006
37. Rawlings DJ, Sommer K, Moreno-Garcia ME: The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol 6:799-812, 2006 (Pubitemid 44631649)
38. Lenz G, Davis RE, Ngo VN, et al: Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319:1676-1679, 2008 (Pubitemid 351432507)
39. Davis RE, Ngo VN, Lenz G, et al: Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88-92, 2010
40. Compagno M, Lim WK, Grunn A, et al: Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459:717-721, 2009
41. Kato M, Sanada M, Kato I, et al: Frequent inactivation of A20 in B-cell lymphomas. Nature 459:712-716, 2009
42. Novak U, Rinaldi A, Kwee I, et al: The NF- {kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 113:4918-4921, 2009
43. Schmitz R, Hansmann ML, Bohle V, et al: TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 206:981-989, 2009
44. Monti S, Savage KJ, Kutok JL, et al: Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105:1851-1861, 2005
45. Lenz G, Wright G, Dave SS, et al: Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313-2323, 2008
46. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996 (Pubitemid 26272076)
47. Schraders M, de Jong D, Kluin P, et al: Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation. J Pathol 205: 329-335, 2005 (Pubitemid 40253923)
48. Leich E, Salaverria I, Bea S, et al: Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 114:826-834, 2009
49. McDonnell TJ, Deane N, Platt FM, et al: Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79-88, 1989 (Pubitemid 19098870)
50. Roulland S, Navarro JM, Grenot P, et al: Follicular lymphoma-like B cells in healthy individuals: A novel intermediate step in early lymphomagenesis. J Exp Med 203:2425-2431, 2006 (Pubitemid 44664612)
51. Cheung KJ, Johnson N, Affleck J, et al: Acquired TNFRSF14 mutations in follicular lymphoma are associated with inferior prognosis. Cancer Res 70:9166-9174, 2010
52. Höglund M, Sehn L, Connors JM, et al: Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer 39:195-204, 2004 (Pubitemid 38209580)
53. Gaidano G, Hauptschein RS, Parsa NZ, et al: Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 80:1781-1787, 1992
54. Cheung KJ, Shah SP, Steidl C, et al: Genomewide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 113: 137-148, 2009
55. O'Shea D, O'Riain C, Taylor C, et al: The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 112:3126-3129, 2008
56. Pinyol M, Cobo F, Bea S, et al: P16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 91:2977-2984, 1998 (Pubitemid 28227549)
57. Davies AJ, Lee AM, Taylor C, et al: A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia 19:1459-1465, 2005 (Pubitemid 41136342)
58. Dave SS, Wright G, Tan B, et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004 (Pubitemid 39507628)
59. Farinha P, Masoudi H, Skinnider BF, et al: Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106:2169-2174, 2005
60. Byers RJ, Sakhinia E, Joseph P, et al: Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood 111:4764-4770, 2008
61. Banks PM, Chan J, Cleary ML, et al: Mantle cell lymphoma: A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 16:637-640, 1992
62. Campo E, Raffeld M, Jaffe ES: Mantle-cell lymphoma. Semin Hematol 36:115-127, 1999 (Pubitemid 29214065)
63. Fernàndez V, Salamero O, Espinet B, et al: Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 70:1408-1418, 2010
64. Bosch F, Lopez-Guillermo A, Campo E, et al: Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors. Cancer 82:567-575, 1998 (Pubitemid 28112997)
65. Rosenwald A, Wright G, Wiestner A, et al: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3:185-197, 2003 (Pubitemid 37443390)
66. Sherr CJ, McCormick F: The RB and p53 pathways in cancer. Cancer Cell 2:103-112, 2002 (Pubitemid 41039110)
67. Fu K, Weisenburger DD, Greiner TC, et al: Cyclin D1-negative mantle cell lymphoma: A clinico-pathological study based on gene expression profiling. Blood 106:4315-4321, 2005 (Pubitemid 41775942)
68. Pinyol M, Hernandez L, Cazorla M, et al: Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 89:272-280, 1997 (Pubitemid 26428202)
69. Beà S, Tort F, Pinyol M, et al: BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61:2409-2412, 2001 (Pubitemid 32685815)
70. Hernández L, Bea S, Pinyol M, et al: CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res 65: 2199-2206, 2005 (Pubitemid 40490128)
71. Pinyol M, Bea S, Pla L, et al: Inactivation of RB1 in mantle cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood 109:5422-5429, 2007 (Pubitemid 46890565)
72. Ott G, Kalla J, Ott MM, et al: Blastoid variants of mantle cell lymphoma: Frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 89:1421-1429, 1997 (Pubitemid 27080007)
73. Schaffner C, Idler I, Stilgenbauer S, et al: Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci U S A 97:2773-2778, 2000 (Pubitemid 30159247)
74. Greiner TC, Moynihan MJ, Chan WC, et al: p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87:4302-4310, 1996 (Pubitemid 26152272)
75. Hartmann EM, Campo E, Wright G, et al: Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 116:953-961, 2010
76. Rudelius M, Pittaluga S, Nishizuka S, et al: Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108:1668-1676, 2006 (Pubitemid 44316136)
77. Cerchietti LC, Yang SN, Shaknovich R, et al: A peptomimetic inhibitor of BCL6 with potent anti-lymphoma effects in vitro and in vivo. Blood 113:3397-3405, 2009